Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Watch the share price. It's not huge. It's not even a done deal. imun has the same cash problems as stab and they have no revenues. And the 5% of imun shares that are supposed to be part of this agreement if it ever gets done - any idea how much that is worth?
That’s huge
About this latest deal:
Sounds good, but deal with imun? Anyone check their financials? No revenues,little cash - I'd be quick to take profits on this news. But that's just me.
Statera Biopharma Shares Rise After Rights Deal With Immune Therapeutics
5:55 pm ET April 27, 2022 (Dow Jones) Print
By Stephen Nakrosis
Shares of Statera Biopharma Inc. were trading higher in Wednesday's after-hours market, following news the company entered a strategic agreement with Immune Therapeutics Inc. to sell rights to naltrexone and met-enkephalin.
At 5:46 p.m. ET, Statera shares were trading 52.3% higher at 31 cents each. Volume in the after-hours session topped 8.7 million shares.
The stock finished the day's regular session with a 1.23% loss, closing at just under 21 cents a share. The stock hit a 52-week low of fractionally above 20 cents a share earlier in the day.
Under the expected terms of the deal, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. Statera will also receive payments for, among other things, achievement of revenue-based milestones, new indications and royalties, in exchange for its rights to any product containing low-dose naltrexone as an active ingredient, the companies said.
In aggregate, the deal could generate over $400 million in non-dilutive payments to Statera, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
Bye bye shorts. Start a go fund me.
how can you put a stop loss on book shares which are still held by the transfer agent?
and everyone who bought the private placements in Cytocom 3 years ago. Everybody lost it all, me included
Looks like the spring is broken. Statera received another warning about Nasdaq delisting, this one for not filing financials. IMO bankruptcy is a real possibility. Pitiful to see how they decimated cbli shareholders.
How about a falling spring!
You know what they say about a falling knife.
LOL - that can end very bad. Exciting news over Easter and they are screwed
Stock is being naked shorted to death. Yesterday they had 481,336 shares naked shorted. 54.24% of yesterday volume was shorlted.
After private placement - don’t think so!
i did thanks. STAB has had an unfortunate run , but it has potential . They shorted the hell out of it and if you look , the upside has a lot of potential .
--
i have a great entry and will ride this out for some time.
--
Better double check that reverse split. I might have gotten this one mixed up with a different stock I was watching. Can't find anything about it right now. Thought I read there would be a vote on a r/s within 45 days, but I could be wrong. So do your own research.
Any update on this?
Look at recent filing where reverse split AND increase in authorized share was discussed. Usually a company does one or the other. Doing both opens the dilution floodgates.
Good news Too!!
Thanks Saw that... well they are due on the 10-k , 15 days max , lets see.
You're welcome. They're filing late as well so who knows what's current.. NT 10-K filed 31-March.
BooDOg... thanks .. I though Finviz was off some also, appreciate the feedback.
Stockholders’ equity (deficit):
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2021 and December 31, 2020; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020
— —
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2021 and 25,000,000 shares authorized as of December 31, 2020; 32,095,520 shares issued and outstanding as of September 30, 2021 and 13,376,062 shares issued and outstanding as of December 31, 2020
Finviz is off a bit...
https://finviz.com/quote.ashx?t=STAB
I was just looking at this for a quick play. Not going to. This company looks like a complete dilution machine. Might add it to my list just to see if I'm looking at it right after my 2 second glance.
What is the Share Structure on the A/S , I see the O/S.
Thanks
It was March 22 ....
the company is destined for the OTC market ...
a total failure !!!
For anyone keeping stab on their watchlist, check out yesterday's 8-K filing if you have a strong stomach. Directors resigning, more NASDAQ compliance issues, no annual report filed on due date, violation of loan covenants, most of its cash seized. What a mess cytocom ceo has made out of this merger with cbli.
Not surprising though, for anyone who actually read the other company filings.
As stab struggles to hold above 30 cents, is anyone actually buying more and more shares as the price goes lower and lower? I have heard this referred to as "dilution insurance". But for companies like stab with no cash, huge losses, and forced into reverse splits and massive dilution, it doesn't seem like a good idea. I have seen followers of this dilution insurance strategy stuck with 100's of millions of worthless shares. Just wondering if anyone recommending it for stab.
So quiet around here. Where did everyone go? Let me guess. Everyone bought at $.33 and sold yesterday at $.35 lol.
For anyone who missed it, here's the latest facts as reported by stab management:
Completed another fund raise. This one placed 12.5 million shares plus warrants for another 25 million shares at $.45 and $.5625/ unit (each unit contained 1 share and 2 warrants). The company netted $4.8 million cash. It also lowered the exercise price of 2 million warrants from the prior offering from $1 to $.43 (not positive about this but I believe I read it somewhere). Also granted options to purchase 1.8 million shares at $.43 with 2.6 million warrants.
So recap:
Prior offering raised about $1.8 million with 2 million shares of dilution plus warrants for 2 million more shares of dilution at $.43.
Latest offering raised about $4.8 million with 12.5 million shares of dilution plus 25 million warrants plus options for 1.8 million shares and warrants for an additional 3.6 million shares. All at prices about half of the prior offering. Here's a link to the latest report in case I got any of the details wrong:
https://ih.advfn.com/stock-market/NASDAQ/statera-biopharma-STAB/stock-news/87654468/current-report-filing-8-k
See the pattern of more dilution at lower and lower prices? The cash from the prior offering should be just about gone by now, and this new $4.8 million might last 2 months (based on the latest financial reports). No wonder a reverse split and increase in authorized shares is coming (as reported by the company itself). No wonder its NASDAQ listing is in jeopardy (also as reported by the company itself). No wonder the price is under 50 cents.
[b"]Keep STAB stock on your Watch List as biopharmaceutical companies are increasing in value as clinical research studies intensify. Link to more news at https://www.staterabiopharma.com/"
https://www.marketwatch.com/press-release/biopharma-stocks-targeting-crohns-disease-in-137-billion-market-stab-arna-gild-and-rdhl-2022-03-16
Amazing to see shorters still around here, LOL!!!!
I am still holding my STAB shares.I have time.
Amazed to see some people still hanging on all the way down from $7. Just wondering, did shareholders of the cytocom half of this merger realize its terrible financial condition or was that kept hidden because it was a private company?
The bottom line is the drug will work for crohn's disease with no side effects. However, they have no money to do the Phase 3 trials. Not sure how far 5.7 million will get them. They will probably continue to need to raise more so further dilution will occur. This is a long term play but how it all works out no one knows for sure.
Stock at 34 cents, down from $7 not too long ago, and $1 recently. Real money maker for everyone buying at 60 or 70 cents and looking for multiple dollars.
Well done lovemelongtime. You are right, dont listen to shorters.
No need to listen to anything I say. Everything anyone needs to know is in the company's financials and other filings. If reverse split, increase in authorized shares, possible Nasdaq delisting, and more offerings at lower and lower prices sounds like reasons to buy, have at it.
Followers
|
78
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3504
|
Created
|
05/13/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |